94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Xi-Feng Wang1
Lu-Ri Bao2Ta-La Hu1Rui-Feng Xu1Wu-Niri Gao1
Jing-Yuan Wang2Jian-Rong Zhao1Zhen-Li Fu3Shu-Fang Wang4*Yan Meng1*- 1Department of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
- 2Department of Pathology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot, China
- 3Department of Hemodialysis, The No. 2 Hospital of Hohhot, Hohhot, China
- 4The First Department of Specialty Medicine, Inner Mongolia Corps Hospital of The Chinese People’s Armed Police Force, Hohhot, China
A Corrigendum on
Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by Wang X-F, Bao L-R, Hu T-L, Xu R-F, Gao W-N, Wang J-Y, Zhao J-R, Fu Z-L, Wang S-F and Meng Y (2025). Front. Pharmacol. 15:1440907. doi: 10.3389/fphar.2024.1440907
In the published article, there was an error in the Author list, and the order of authors “Yan Meng” and “Shu-Fang Wang” was incorrect. The corrected author list appears below.
“Xi-Feng Wang1, Lu-Ri Bao2, Ta-La Hu1, Rui-Feng Xu1, Wu-Niri Gao1, Jing-Yuan Wang2, Jian-Rong Zhao1, Zhen-Li Fu3, Shu-Fang Wang4* and Yan Meng1*”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: eculizumab, FAERS, adverse drug events, adverse drug reaction monitoring, ADRM
Citation: Wang X-F, Bao L-R, Hu T-L, Xu R-F, Gao W-N, Wang J-Y, Zhao J-R, Fu Z-L, Wang S-F and Meng Y (2025) Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database. Front. Pharmacol. 16:1558930. doi: 10.3389/fphar.2025.1558930
Received: 11 January 2025; Accepted: 22 January 2025;
Published: 07 February 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Wang, Bao, Hu, Xu, Gao, Wang, Zhao, Fu, Wang and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yan Meng, bWJhbzEyNEBxcS5jb20=; Shu-Fang Wang, d3NoZnh5ekAxNjMuY29t